Insider Selling: Exelixis, Inc. (EXEL) Director Sells 40,000 Shares of Stock
Exelixis, Inc. (NASDAQ:EXEL) Director Vincent T. Marchesi sold 40,000 shares of Exelixis stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $19.50, for a total value of $780,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Exelixis stock traded down $0.38 during trading on Friday, hitting $19.20. 2,820,100 shares of the company were exchanged, compared to its average volume of 3,691,168. The firm has a market capitalization of $6.08 billion, a P/E ratio of 38.39 and a beta of 2.02. Exelixis, Inc. has a 1-year low of $18.50 and a 1-year high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.12. The company had revenue of $186.10 million during the quarter, compared to analyst estimates of $157.37 million. Exelixis had a return on equity of 65.68% and a net margin of 48.17%. The company’s revenue for the quarter was up 88.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.06 EPS. equities research analysts expect that Exelixis, Inc. will post 1.03 EPS for the current fiscal year.
A number of brokerages recently commented on EXEL. Cann reiterated a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research report on Wednesday, May 30th. ValuEngine upgraded Exelixis from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 17th. Needham & Company LLC decreased their target price on Exelixis from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 11th. Piper Jaffray Companies decreased their target price on Exelixis from $33.00 to $29.00 and set an “overweight” rating for the company in a research report on Thursday, May 10th. Finally, Zacks Investment Research upgraded Exelixis from a “sell” rating to a “hold” rating in a research report on Monday, April 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $32.67.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.